Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients.

• Status: Completed
• Trial end date: 2016-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The Purpose of this study is to determine if the Febuxostat has an effect on endothelial dysfunction on hemodialysis patients.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Ain Shams University
• Treatments: Febuxostat

Criteria

Inclusion Criteria:

• Outpatients on maintenance hemodialysis.

• Age from 18-70 years old.

• Serum Uric Acid level 7.0 mg/dL or more.

• Stable clinical condition (no hospitalization in the previous 3 months)

• Informed consent in accordance with the Declaration of Helsinki.

Exclusion Criteria:

• Current urate-lowering therapy. (allopurinol, probenecid, bucolome, febuxostat)

• History of hypersensitivity to febuxostat.

• Current treatment with mercaptopurine, azathioprine, pyrazinamide, or ethambutol.

• Participant in an another clinical trial within the past 4 weeks.

• Judged to be unsuitable as a subject by the attending physician